# US 2024/0002849 A1 · Treatment of fuchs' endothelial corneal dystrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002849 A1
- Document ID: US20240002849A1
- Status: Published application
- Kind: A1
- Application number: 18/053,559
- Filed: 2022-11-08
- Published: 2024-01-04
- Earliest claimed: 2017-03-10
- Assignees: Board of Regents, The University of Texas System; University of Massachusetts
- Applicants: The Board of Regents of the University of Texas System; University of Massachusetts
- Inventors: Venkateswara V. MOOTHA; David R. COREY; Jiaxin HU; Jonathan K. WATTS
- Web page: https://patentgrep.com/patent/US20240002849A1

## CPC

- A61P 27/02: Ophthalmic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/12: Ketones
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2310/533: having a mismatch or nick in at least one of the strands
- C12N 2320/34: Allele or polymorphism specific uses
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).

## Claims

### Claim at position 1

1-266. (canceled)

### Claim 267

A method of treating a subject with Fuchs endothelial corneal dystrophy comprising administering a gene editing construct and at least one guide RNA that targets intron 2 of TCF4 or the 3′-UTR of DMPK.

### Claim 268 (depends on 267)

The method of claim 267, wherein the gene editing construct is an inactivated Cas9 or Cas12a construct.

### Claim 269 (depends on 268)

The method of claim 268, wherein administration of the at least one gene editing construct is concurrent to administration of the at least one oligonucleotide.

### Claim 270 (depends on 268)

The method of claim 268, wherein administration of the at least one gene editing construct is subsequent to administration of the at least one oligonucleotide.

### Claim 271

A composition comprising two gene editing RNAs of 30 to 120 nucleotides in length that flank repeat sequences in the genomic region corresponding to intron 2 of TCF4 or the 3′-UTR of DMPK.

### Claim 272 (depends on 271)

The composition of claim 271, wherein one or both of said gene editing RNAs is/are complementary to a target DNA sequence in or flanking the CTG triplet repeat locus in TCF4 or DMPK.

### Claim 273 (depends on 271)

The composition of claim 271, further comprising one or more guide RNAs.

### Claim 274 (depends on 273)

The composition of claim 273, further comprising a template DNA sequence designed to facilitate homology-directed recombination of the genomic DNA in the targeted region.

### Claim 275 (depends on 273)

The composition of claim 273, wherein the composition does not comprise a template DNA sequence designed to facilitate homology-directed recombination of the genomic DNA in the targeted region.

### Claim 276 (depends on 273)

The composition of claim 273, wherein at least one of the guide RNAs comprises the sequence of any of SEQ ID NOS: 81-130.

### Claim 277 (depends on 274)

A method of performing RNA guided excision of a (CTG,CAG)n DNA tract comprising contacting a cell with the composition of claim 274.

### Claim 278 (depends on 277)

The method of claim 277, wherein said gene editing RNA sequences comprises one or more chemically modified nucleobases.

### Claim 279 (depends on 278)

The method of claim 278, wherein said one or more chemically-modified nucleobases is a nuclease-resistant modification.

### Claim 280

A composition comprising a repeat-RNA-targeting guide sequence comprising at least 2 CAG repeats that binds to CUG repeat RNA corresponding to intron 2 of TCF4 or the 3′-UTR of DMPK.

### Claim 281 (depends on 280)

The composition of claim 280, wherein guide sequence is a CUG repeat RNA targeting guide RNA comprising a poly-CAG spacer sequence, and a RNA targeting nuclease-dead Cas9 or other RNA targeting construct is co-administered with said guide sequences.

### Claim 282 (depends on 280)

The composition of claim 280, wherein the guide RNA comprises the sequence CAG or sequence of any of SEQ ID NOS: 68-73.

### Claim 283 (depends on 280)

The composition of claim 280, further comprising an inactivated CRISPR nuclease.

### Claim 284 (depends on 280)

The composition of claim 280, further comprising an RNA-targeting construct.

### Claim 285 (depends on 284)

The composition of claim 284, wherein the RNA-targeting construct is present as a separate DNA molecule, mRNA, or protein.

### Claim 286 (depends on 280)

The composition of claim 280, wherein said repeat-RNA-targeting guide sequence comprises one or more chemically modified nucleobases.
